Last year, the Therapeutic Goods Administration approved the use of Ozempic to help reduce kidney disease progression in people with type 2 diabetes and chronic kidney disease
This trial tests two treatments, bimagrumab and semaglutide, to evaluate their effectiveness for weight loss in individuals who are overweight or have obesity, both separately and in combination
Mitigating the risk of disease exacerbations, managing symptoms, and addressing the underlying inflammation have remained the central objectives of asthma therapy [4, 5]
It had earlier updated the product information to include the small risk of severe acute pancreatitis in patients taking GLP-1s
Semaglutide affects blood sugar levels, which may trigger headaches in some
L.JainP.HebbarS.DhasN.et al (2025)